1. Giese, A., Bjerkvig, R., Berens, M. E. & Westphal, M. Cost of migration: Invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21, 1624–1636. https://doi.org/10.1200/JCO.2003.05.063 (2003).
2. Louis, D. N. et al. The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta
Neuropathol. 131, 803–820. https://doi.org/10.1007/s00401-016-1545-1 (2016).
3. Metellus, P. et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with
dismal prognosis. Acta Neuropathol. 120, 719–729. https://doi.org/10.1007/s00401-010-0777-8 (2010).
4. Wijnenga, M. M. J. et al. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: Assessment of
TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol. 134, 957–959. https://doi.org/10.1007/s00401-017-1781-z (2017).
5. Aibaidula, A. et al. Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol. 19, 1327–1337. https://
doi.org/10.1093/neuonc/nox078 (2017).
6. Tabouret, E. et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol. 132, 625–634. https://doi.org/10.1007/s00401-016-1611-8 (2016).
7. Cancer Genome Atlas Research, N et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J.
Med. 372, 2481–2498. https://doi.org/10.1056/NEJMoa1402121 (2015).
8. Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47, 458–468 (2015).
9. Brat, D. J. et al. cIMPACT-NOW update 3: Recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with
molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 136, 805–810. https://doi.org/10.1007/s00401-018-1913-0
(2018).
10. Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol 23, 1231–1251.
https://doi.org/10.1093/neuonc/noab106 (2021).
11. Berzero, G. et al. IDH-wildtype lower-grade diffuse gliomas: The importance of histological grade and molecular assessment for
prognostic stratification. Neuro Oncol. 23, 955–966. https://doi.org/10.1093/neuonc/noaa258 (2021).
12. Tesileanu, C. M. S. et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO
grade IV: A confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 22, 515–523. https://doi.org/10.1093/neuonc/noz200
(2020).
13. Ding, H. et al. Prediction of IDH status through MRI features and enlightened reflection on the delineation of target volume in
low-grade gliomas. Technol. Cancer Res. Treat. 18, 1533033819877167. https://doi.org/10.1177/1533033819877167 (2019).
14. Park, Y. W. et al. Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower
grade gliomas. AJNR Am. J. Neuroradiol. 39, 37–42. https://doi.org/10.3174/ajnr.A5421 (2018).
15. van Lent, D. I., van Baarsen, K. M., Snijders, T. J. & Robe, P. Radiological differences between subtypes of WHO 2016 grade II–III
gliomas: A systematic review and meta-analysis. Neurooncol Adv. 2, 044. https://doi.org/10.1093/noajnl/vdaa044 (2020).
16. Lee, D., Riestenberg, R. A., Haskell-Mendoza, A. & Bloch, O. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features
of glioblastoma, WHO grade IV: A single-institution case series and review. J. Neurooncol. 152, 89–98. https://doi.org/10.1007/
s11060-020-03677-4 (2021).
17. Villanueva-Meyer, J. E. et al. MRI features and IDH mutational status of grade II diffuse gliomas: Impact on diagnosis and prognosis. AJR Am. J. Roentgenol. 210, 621–628. https://doi.org/10.2214/AJR.17.18457 (2018).
18. Weller, M. et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide
profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 129, 679–693. https://d
oi.o
rg/1 0.1 007/
s00401-015-1409-0 (2015).
19. Izquierdo, C. et al. Radiological characteristics and natural history of adult IDH-wildtype astrocytomas with TERT promoter
mutations. Neurosurgery 85, E448–E456. https://doi.org/10.1093/neuros/nyy513 (2019).
20. Wijnenga, M. M. J. et al. The impact of surgery in molecularly defined low-grade glioma: An integrated clinical, radiological, and
molecular analysis. Neuro Oncol. 20, 103–112. https://doi.org/10.1093/neuonc/nox176 (2018).
21. Delfanti, R. L. et al. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: Implications for IDH,
1p/19q and ATRX status. J. Neurooncol. 135, 601–609. https://doi.org/10.1007/s11060-017-2613-7 (2017).
22. Yamauchi, T. et al. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II
and III gliomas. Brain Tumor Pathol. 35, 148–158. https://doi.org/10.1007/s10014-018-0321-4 (2018).
23. Hyare, H. et al. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status. Eur. J. Radiol. 114,
120–127. https://doi.org/10.1016/j.ejrad.2019.03.003 (2019).
Scientific Reports |
Vol:.(1234567890)
(2023) 13:23 |
https://doi.org/10.1038/s41598-022-25928-2
www.nature.com/scientificreports/
24. Patel, T. et al. The role of extent of resection in IDH1 wild-type or mutant low-grade gliomas. Neurosurgery 82, 808–814. https://
doi.org/10.1093/neuros/nyx265 (2018).
25. Wang, P., Luo, C., Hong, P. J., Rui, W. T. & Wu, S. The role of surgery in IDH-wild-type lower-grade gliomas: Threshold at a high
extent of resection should be pursued. Neurosurgery 88, 1136–1144. https://doi.org/10.1093/neuros/nyab052 (2021).
26. Aoki, K. et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 20, 66–77. https://doi.org/
10.1093/neuonc/nox132 (2018).
27. Lu, J., Li, X. & Li, H. A radiomics feature-based nomogram to predict telomerase reverse transcriptase promoter mutation status
and the prognosis of lower-grade gliomas. Clin. Radiol. https://doi.org/10.1016/j.crad.2022.04.005 (2022).
28. Choi, Y. S. et al. Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics.
Neuro Oncol. 23, 304–313. https://doi.org/10.1093/neuonc/noaa177 (2021).
29. Villanueva-Meyer, J. E., Mabray, M. C. & Cha, S. Current clinical brain tumor imaging. Neurosurgery 81, 397–415. https://doi.org/
10.1093/neuros/nyx103 (2017).
30. Pallud, J. et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas.
Ann. Neurol. 60, 380–383. https://doi.org/10.1002/ana.20946 (2006).
31. Duffau, H., Peggy Gatignol, S. T., Mandonnet, E., Capelle, L. & Taillandier, L. Intraoperative subcortical stimulation mapping of
language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere. J. Neurosurg. 109,
461–471. https://doi.org/10.3171/JNS/2008/109/9/0461 (2008).
32. Motomura, K. et al. Surgical benefits of combined awake craniotomy and intraoperative magnetic resonance imaging for gliomas
associated with eloquent areas. J. Neurosurg. 127, 790–797. https://doi.org/10.3171/2016.9.JNS16152 (2017).
33. Motomura, K. et al. Supratotal resection of diffuse frontal lower grade gliomas with awake brain mapping, preserving motor,
language, and neurocognitive functions. World Neurosurg. 119, 30–39. https://doi.org/10.1016/j.wneu.2018.07.193 (2018).
34. Motomura, K. et al. Navigated repetitive transcranial magnetic stimulation as preoperative assessment in patients with brain
tumors. Sci. Rep. 10, 9044. https://doi.org/10.1038/s41598-020-65944-8 (2020).
35. Motomura, K. et al. Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain
mapping. J. Neurooncol. 153, 361–372. https://doi.org/10.1007/s11060-021-03776-w (2021).
36. Motomura, K. et al. Neurocognitive and functional outcomes in patients with diffuse frontal lower-grade gliomas undergoing
intraoperative awake brain mapping. J. Neurosurg. 132, 1683–1691. https://doi.org/10.3171/2019.3.JNS19211 (2019).
37. Motomura, K. et al. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma
with the unmethylated MGMT promoter: A multicenter study. Cancer 117, 1721–1730. https://d
oi.o
rg/1 0.1 002/c ncr.2 5637 (2011).
Acknowledgements
The authors thank Mr. Hiroyasu Yamamoto, Mr. Kyohei Koyama, Mr. Daisuke Hara, and Mr. Yasuyuki Matsui
(Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan) for their technical assistance.
Author contributions
Experimental design: K.M., R.S. Collection and assembly of data: Y.K., T.N. J.Y., H.S. Analysis and interpretation
of the data: Y.K., K.M., F.O., K.A., R.S. Manuscript writing: Y.K., K.M. Final approval of manuscript: all authors.
Patient informed consent was waived due to the retrospective nature of the study approved by the Ethics Committee of Nagoya University Hospital.
Funding
This work was supported by a Grant-in-Aid for Scientific Research (C) awarded to K.M. (no. 21K09174) from
the Japan Society for the Promotion of Science (JSPS). We have no financial disclosures to make or conflicts of
interest to declare.
Competing interests The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to K.M.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2022
Scientific Reports |
(2023) 13:23 |
https://doi.org/10.1038/s41598-022-25928-2
Vol.:(0123456789)
...
論文の公開元へ
